<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843982</url>
  </required_header>
  <id_info>
    <org_study_id>YSY202001</org_study_id>
    <nct_id>NCT04843982</nct_id>
  </id_info>
  <brief_title>Immunoinflammatory Regulation of Esketamine in Septic Patients</brief_title>
  <official_title>Effects of Esketamine Combined With Propofol for Sedation on Systemic Inflammation and Immune Function in Septic Patients in the ICU: a Single-center, Non-blind, Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies have shown that excessive systemic inflammatory response and concomitant&#xD;
      immunosuppression are the main cause of early death in patients with sepsis. Therefore, it is&#xD;
      very important to reduce excessive inflammation and improve immunosuppression in the acute&#xD;
      phase of sepsis. Clinical studies have shown that esketamine combined with propofol for&#xD;
      sedation has been proven to be safe and effective for septic patients in the ICU due to its&#xD;
      cardiovascular stability. Previous studies have demonstrated that esketamine has&#xD;
      anti-inflammatory effects against depression and surgical stress. Our preliminary&#xD;
      experimental studies have found that esketamine had strong anti-inflammatory effects in the&#xD;
      acute phase of sepsis. However, it is not clear whether esketamine could reduce excessive&#xD;
      inflammation and improve immunosuppression in septic patients primarily sedated with a&#xD;
      continuous infusion of propofol.&#xD;
&#xD;
      This intervention study is to investigate whether three consecutive days of intravenous&#xD;
      esketamine infusions via infusion pump (0.07 mg/kg/h) could reduce excessive inflammation and&#xD;
      improve immunosuppression in septic patients requiring mechanical ventilation in the ICU&#xD;
      under sedation primarily with propofol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum concentration of inflammatory cytokines (0 h)</measure>
    <time_frame>0 hour after study inclusion</time_frame>
    <description>Interleukin (IL)-6, tumor necrosis factor (TNF)-α, IL-2, IL-4, IL-10, IL-17A, and interferon (IFN)-γ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of inflammatory cytokines (48 h)</measure>
    <time_frame>48 hours after study inclusion</time_frame>
    <description>IL-6, TNF-α, IL-2, IL-4, IL-10, IL-17A, and IFN-γ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentration of inflammatory cytokines (72 h)</measure>
    <time_frame>72 hours after study inclusion</time_frame>
    <description>IL-6, TNF-α, IL-2, IL-4, IL-10, IL-17A, and IFN-γ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute number of lymphocyte subsets in the peripheral blood (0 h)</measure>
    <time_frame>0 hour after study inclusion</time_frame>
    <description>CD3(+), CD3(+) CD4(+), CD3(+) CD8(+), CD3(-) CD16(+) CD56(+) , and CD19(+) cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute number of lymphocyte subsets in the peripheral blood (48 h)</measure>
    <time_frame>48 hours after study inclusion</time_frame>
    <description>CD3(+), CD3(+) CD4(+), CD3(+) CD8(+), CD3(-) CD16(+) CD56(+) , and CD19(+) cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute number of lymphocyte subsets in the peripheral blood (72 h)</measure>
    <time_frame>72 hours after study inclusion</time_frame>
    <description>CD3(+), CD3(+) CD4(+), CD3(+) CD8(+), CD3(-) CD16(+) CD56(+) , and CD19(+) cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Length of stay in the ICU</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of atrial natriuretic peptide (ANP) (0 h)</measure>
    <time_frame>0 hour after study inclusion</time_frame>
    <description>ANP is secreted primarily by atrial cardiomyocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of atrial natriuretic peptide (ANP) (48h)</measure>
    <time_frame>48 hours after study inclusion</time_frame>
    <description>ANP is secreted primarily by atrial cardiomyocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of atrial natriuretic peptide (ANP) (72h)</measure>
    <time_frame>72 hours after study inclusion</time_frame>
    <description>ANP is secreted primarily by atrial cardiomyocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute physiology and chronic health evaluation (APACHE) Ⅱ score</measure>
    <time_frame>0 hour after study inclusion</time_frame>
    <description>0-67, higher scores correspond to more severe disease and a higher risk of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute physiology and chronic health evaluation (APACHE) Ⅱ score</measure>
    <time_frame>24 hours after study inclusion</time_frame>
    <description>0-67, higher scores correspond to more severe disease and a higher risk of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute physiology and chronic health evaluation (APACHE) Ⅱ score</measure>
    <time_frame>48 hours after study inclusion</time_frame>
    <description>0-67, higher scores correspond to more severe disease and a higher risk of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute physiology and chronic health evaluation (APACHE) Ⅱ score</measure>
    <time_frame>72 hours after study inclusion</time_frame>
    <description>0-67, higher scores correspond to more severe disease and a higher risk of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential organ failure assessment (SOFA) score</measure>
    <time_frame>0 hour after study inclusion</time_frame>
    <description>0-43, higher scores correspond to more severe sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential organ failure assessment (SOFA) score</measure>
    <time_frame>24 hours after study inclusion</time_frame>
    <description>0-43, higher scores correspond to more severe sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential organ failure assessment (SOFA) score</measure>
    <time_frame>48 hours after study inclusion</time_frame>
    <description>0-43, higher scores correspond to more severe sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential organ failure assessment (SOFA) score</measure>
    <time_frame>72 hours after study inclusion</time_frame>
    <description>0-43, higher scores correspond to more severe sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation time after inclusion</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Patients requiring mechanical ventilation after study inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospital length of stay</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>Total length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection complications</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>Pulmonary infection, urinary tract infection, bloodstream infections, etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>Mortality rates for the entire period of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day readmission rate</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>Percentage of readmission to hospital within 90 days of study inclusion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Esketamine</condition>
  <condition>Sepsis</condition>
  <condition>Inflammatory Response</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>esketamine plus propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After inclusion, patients are sedated primarily with propofol (0-3 mg/kg/h) using a microinfusion pump and adjusted according to the depth of sedation (Richmond Agitation Sedation Scale (RASS): 0 to -2).&#xD;
After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>After inclusion, patients are sedated primarily with propofol (0-3 mg/kg/h) using a microinfusion pump and adjusted according to the depth of sedation (Richmond Agitation Sedation Scale (RASS): 0 to -2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine hydrochloride</intervention_name>
    <description>After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.</description>
    <arm_group_label>esketamine plus propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years old ≤ age ≤60 years old;&#xD;
&#xD;
          -  SOFA score ≥2;&#xD;
&#xD;
          -  Mechanical ventilation should be required for at least 24 hours when included in the&#xD;
             study;&#xD;
&#xD;
          -  Informed consent is obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years old or ≥ 60 years old;&#xD;
&#xD;
          -  Previous solid organ or bone marrow transplantation;&#xD;
&#xD;
          -  Autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.), or&#xD;
             hematologic malignancies (leukemia and lymphoma, etc.);&#xD;
&#xD;
          -  Received radiotherapy or chemotherapy within the past 30 days, or received&#xD;
             immunosuppressant drugs (tripterygium wilfordii, mycophenolate mofetil,&#xD;
             cyclophosphamide, FK506, etc.), or continuous treatment with prednisolone more than 10&#xD;
             mg/day (or equivalent doses of the other hormones);&#xD;
&#xD;
          -  Unstable angina pectoris or myocardial infarction in the past six months;&#xD;
&#xD;
          -  Acute brain injury (traumatic brain injury, subarachnoid hemorrhage, acute ischemic&#xD;
             stroke, acute intracranial hemorrhage, acute intracranial infection, etc.);&#xD;
&#xD;
          -  Poorly controlled hypertension and congestive heart failure;&#xD;
&#xD;
          -  Increased intraocular or intracranial pressure;&#xD;
&#xD;
          -  Chronic kidney disease, received continuous renal replacement therapy in the past 30&#xD;
             days, or acute renal failure requiring CRRT;&#xD;
&#xD;
          -  Severe chronic liver disease (Child-Pugh class B or C);&#xD;
&#xD;
          -  Alcohol dependence, mental illness or severe cognitive impairment;&#xD;
&#xD;
          -  Pregnancy or lactation;&#xD;
&#xD;
          -  Informed consent is not obtained.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiying Yuan, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuhan Union Hospital, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiancheng Zhang, PhD, MD</last_name>
    <phone>+8613554105815</phone>
    <email>zhjcheng1@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiancheng Zhang, PhD, MD</last_name>
      <phone>+8613554105815</phone>
      <email>zhjcheng1@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiying Yuan, Dr.</last_name>
      <phone>+8613995646372</phone>
      <email>yuan_shiying@163.com</email>
    </contact>
    <investigator>
      <last_name>Jiancheng Zhang, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esketamine</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Inflammatory Response</keyword>
  <keyword>Immunosuppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the completion of the study, the original data will be sent to the email address: zhjcheng1@163.com, and the password will be provided after the paper is published.</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Six months after the paper was published</ipd_time_frame>
    <ipd_access_criteria>The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

